Tandem Diabetes Care TNDM International — Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's international — sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's international — sales?
- Tandem Diabetes Care (TNDM) reported international — sales of $86.38M in Q1 2026.
- How has Tandem Diabetes Care's international — sales changed year-over-year?
- Tandem Diabetes Care's international — sales increased by 3.1% year-over-year, from $83.79M to $86.38M.
- What is the long-term trend for Tandem Diabetes Care's international — sales?
- Over 4 years (2021 to 2025), Tandem Diabetes Care's international — sales has grown at a 14.7% compound annual growth rate (CAGR), from $177.89M to $307.8M.
- What does international — sales mean?
- This metric represents the total revenue generated from product sales and services within geographic regions outside of the company's primary domestic market. It serves as a key indicator of the firm's global market penetration and the scalability of its product portfolio in international healthcare systems. Growth in this metric reflects successful expansion efforts and the adoption rate of medical devices in non-domestic territories.